BeiGene, NewBridge Conclude BRUKINSA® Partnership in MENA

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a leading oncology firm, and NewBridge Pharmaceuticals have mutually decided to conclude their partnership in the MENA region. This strategic move is aligned with BeiGene’s aim to directly manage its operations in the area and expand its presence.

The collaboration, initiated in 2020, involved sales, distribution, and commercialization of BRUKINSA® (Zanubrutinib) in the MENA region. BRUKINSA® received approvals from health authorities in multiple territories and is currently marketed in several regions, with more approvals expected. The separation process will be executed in a phased manner, with timelines set from June 2024 to March 31, 2025. Starting June 11, 2024, BeiGene will take over all customer-facing activities, including Medical Affairs, Commercial Operations, and Market Access, utilizing its expanded regional team.

Mohammed Al-Kapany, General Manager of the MENA region at BeiGene, expressed gratitude for NewBridge Pharmaceuticals’ collaboration and emphasized BeiGene’s commitment to a smooth transition and advancing cancer care in the region.

Hisham El Sayed, Executive VP & Regional Head of Commercial, Middle East & Africa for NewBridge Pharmaceuticals, echoed these sentiments, affirming support for BeiGene’s strategic decision and commitment to ensuring a seamless transition.

This strategic shift signifies a significant milestone for BeiGene as it expands globally, aiming to achieve groundbreaking advancements in cancer treatment by 2025. The company remains dedicated to providing innovative and transformative cancer therapies worldwide.

About BeiGene:

BeiGene is a global oncology company focused on developing innovative cancer treatments that are more accessible and affordable for patients worldwide. With a diverse portfolio, BeiGene is accelerating the development of novel therapeutics through internal capabilities and collaborations, aiming to radically improve access to medicines for more patients in need.

About NewBridge Pharmaceuticals:

NewBridge Pharmaceuticals is a regional specialty company dedicated to bridging the access gap and partnering with global pharma and biotech firms to commercialize FDA or EMA-approved innovative therapeutics addressing unmet medical needs in the MENA regions.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter